{"corpus_id":49299569,"paper_sha":"cdb706d22841d6ad289f956884c48de8dbc6b58f","doi":"10.1371/journal.pmed.1002587","arxiv_id":null,"pmid":29912983,"pmcid":"6005466","mag_id":2808725197,"dblp_id":null,"acl_id":null,"title":"Efficacy of melatonin with behavioural sleep-wake scheduling for delayed sleep-wake phase disorder: A double-blind, randomised clinical trial","year":2018,"publication_date":"2018-06-01","venue":"PLoS Medicine","journal":{"name":"PLoS Medicine","pages":null,"volume":"15"},"journal_issn":null,"journal_title":null,"publication_types":["Study","JournalArticle"],"pubmed_pub_types":["Journal Article","Multicenter Study","Randomized Controlled Trial","Research Support, Non-U.S. Gov't"],"s2_fields_of_study":["Medicine"],"reference_count":63,"citation_count":101,"influential_citation_count":2,"is_open_access":true,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":[{"d":"Actigraphy","mj":false,"ui":"D056044"},{"d":"Adolescent","mj":false,"ui":"D000293"},{"d":"Adult","mj":false,"ui":"D000328"},{"d":"Aged","mj":false,"ui":"D000368"},{"d":"Double-Blind Method","mj":false,"ui":"D004311"},{"d":"Female","mj":false,"ui":"D005260"},{"d":"Humans","mj":false,"ui":"D006801"},{"d":"Male","mj":false,"ui":"D008297"},{"d":"Melatonin","mj":false,"qs":[{"q":"therapeutic use","mj":true,"ui":"Q000627"}],"ui":"D008550"},{"d":"Middle Aged","mj":false,"ui":"D008875"},{"d":"New South Wales","mj":false,"ui":"D009517"},{"d":"Sleep","mj":false,"qs":[{"q":"drug effects","mj":true,"ui":"Q000187"}],"ui":"D012890"},{"d":"Sleep Aids, Pharmaceutical","mj":false,"qs":[{"q":"therapeutic use","mj":true,"ui":"Q000627"}],"ui":"D000068776"},{"d":"Sleep Wake Disorders","mj":false,"qs":[{"q":"drug therapy","mj":true,"ui":"Q000188"}],"ui":"D012893"},{"d":"South Australia","mj":false,"ui":"D013021"},{"d":"Victoria","mj":false,"ui":"D014739"},{"d":"Young Adult","mj":false,"ui":"D055815"}],"chemicals":[{"n":"Sleep Aids, Pharmaceutical","ui":"D000068776","reg":"0"},{"n":"Melatonin","ui":"D008550","reg":"JL5DK93RCL"}],"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":"https://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1002587&type=printable","s2_open_access_landing_url":"https://www.semanticscholar.org/paper/cdb706d22841d6ad289f956884c48de8dbc6b58f","s2_open_access_license":"CCBY","s2_open_access_status":"GOLD","pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"Background Delayed Sleep-Wake Phase Disorder (DSWPD) is characterised by sleep initiation insomnia when attempting sleep at conventional times and difficulty waking at the required time for daytime commitments. Although there are published therapeutic guidelines for the administration of melatonin for DSWPD, to our knowledge, randomised controlled trials are lacking. This trial tested the efficacy of 0.5 mg melatonin, combined with behavioural sleep-wake scheduling, for improving sleep initiation in clinically diagnosed DSWPD patients with a delayed endogenous melatonin rhythm relative to patient-desired (or -required) bedtime (DBT). Methods This randomised, placebo-controlled, double-blind clinical trial was conducted in an Australian outpatient DSWPD population. Following 1-wk baseline, clinically diagnosed DSWPD patients with delayed melatonin rhythm relative to DBT (salivary dim light melatonin onset [DLMO] after or within 30 min before DBT) were randomised to 4-wk treatment with 0.5 mg fast-release melatonin or placebo 1 h before DBT for at least 5 consecutive nights per week. All patients received behavioural sleep-wake scheduling, consisting of bedtime scheduled at DBT. The primary outcome was actigraphic sleep onset time. Secondary outcomes were sleep efficiency in the first third of time in bed (SE T1) on treatment nights, subjective sleep-related daytime impairment (Patient Reported Outcomes Measurement Information System [PROMIS]), PROMIS sleep disturbance, measures of daytime sleepiness, clinician-rated change in illness severity, and DLMO time. Findings Between September 13, 2012 and September 1, 2014, 307 participants were registered; 116 were randomised to treatment (intention-to-treat n = 116; n = 62 males; mean age, 29.0 y). Relative to baseline and compared to placebo, sleep onset occurred 34 min earlier (95% confidence interval [CI] −60 to −8) in the melatonin group. SE T1 increased; PROMIS sleep-related impairment, PROMIS sleep disturbance, insomnia severity, and functional disability decreased; and a greater proportion of patients showed more than minimal clinician-rated improvement following melatonin treatment (52.8%) compared to placebo (24.0%) (P < 0.05). The groups did not differ in the number of nights treatment was taken per protocol. Post-treatment DLMO assessed in a subset of patients (n = 43) was not significantly different between groups. Adverse events included light-headedness, daytime sleepiness, and decreased libido, although rates were similar between treatment groups. The clinical benefits or safety of melatonin with long-term treatment were not assessed, and it remains unknown whether the same treatment regime would benefit patients experiencing DSWPD sleep symptomology without a delay in the endogenous melatonin rhythm. Conclusions In this study, melatonin treatment 1 h prior to DBT combined with behavioural sleep-wake scheduling was efficacious for improving objective and subjective measures of sleep disturbances and sleep-related impairments in DSWPD patients with delayed circadian phase relative to DBT. Improvements were achieved largely through the sleep-promoting effects of melatonin, combined with behavioural sleep-wake scheduling. Trial registration This trial was registered with the Australian New Zealand Clinical Trials Registry, ACTRN12612000425897.","claims":[{"public_id":"cl_b1ffd478b5403fa27efe994ac132263d","status":"active","text":"A greater proportion of patients showed more than minimal clinician-rated improvement after melatonin treatment (52.8%) compared to placebo (24.0%) (P < 0.05).","confidence":0.9,"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_b1ffd478b5403fa27efe994ac132263d"},{"public_id":"cl_9a4ef3ee78d12402834682686f38b25c","status":"active","text":"Adverse events including light-headedness, daytime sleepiness, and decreased libido occurred at similar rates between melatonin and placebo groups.","confidence":0.85,"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_9a4ef3ee78d12402834682686f38b25c"},{"public_id":"cl_97249405eb0336afa714e8ed19335f2c","status":"active","text":"Melatonin 0.5 mg fast-release combined with behavioural sleep-wake scheduling improved objective sleep onset time by 34 minutes earlier (95% CI −60 to −8) compared to placebo in DSWPD patients with delayed melatonin rhythm relative to desired bedtime.","confidence":0.95,"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_97249405eb0336afa714e8ed19335f2c"},{"public_id":"cl_c221b205b01eb5c6d7a8c5950dfbdffb","status":"active","text":"Melatonin treatment increased sleep efficiency in the first third of time in bed (SE T1) and reduced PROMIS sleep-related impairment, PROMIS sleep disturbance, insomnia severity, and functional disability compared to placebo.","confidence":0.9,"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_c221b205b01eb5c6d7a8c5950dfbdffb"},{"public_id":"cl_533e0771f5513b49ae0e892a71215e9f","status":"active","text":"Post-treatment dim light melatonin onset (DLMO) assessed in a subset of patients (n = 43) was not significantly different between melatonin and placebo groups.","confidence":0.85,"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_533e0771f5513b49ae0e892a71215e9f"}],"concepts":[{"public_id":"co_2ab5eea3bc7a921909c3449eb7d28021","status":"active","name":"PROMIS sleep-related impairment","description":"A subjective measure of daytime impairment related to sleep, from the Patient Reported Outcomes Measurement Information System.","types":["outcome"],"aliases":[],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_2ab5eea3bc7a921909c3449eb7d28021"},{"public_id":"co_2b19acb9d04032562d045ffbc9be661b","status":"active","name":"sleep efficiency in the first third of time in bed","description":"A secondary outcome measuring sleep efficiency during the first third of the time spent in bed on treatment nights.","types":["outcome"],"aliases":["SE T1"],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_2b19acb9d04032562d045ffbc9be661b"},{"public_id":"co_42fcdb0c61496ec1e6e63160b8c8a981","status":"active","name":"behavioural sleep-wake scheduling","description":"A behavioural intervention consisting of scheduling bedtime at the patient's desired bedtime, combined with melatonin treatment.","types":["intervention"],"aliases":[],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_42fcdb0c61496ec1e6e63160b8c8a981"},{"public_id":"co_4a6b3bc3f8b12d5f6adda7a2edb61f8c","status":"active","name":"melatonin 0.5 mg fast-release","description":"The specific dose and formulation of melatonin administered 1 hour before desired bedtime in this trial.","types":["intervention"],"aliases":[],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_4a6b3bc3f8b12d5f6adda7a2edb61f8c"},{"public_id":"co_4bcc3c1a9beeefc6737630318400c75f","status":"active","name":"PROMIS sleep disturbance","description":"A subjective measure of sleep disturbance from the Patient Reported Outcomes Measurement Information System.","types":["outcome"],"aliases":[],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_4bcc3c1a9beeefc6737630318400c75f"},{"public_id":"co_4c462d96e6d960e370e4c4f49ce836e2","status":"active","name":"delayed sleep-wake phase disorder","description":"The clinical condition studied, characterized by delayed sleep initiation and difficulty waking at conventional times.","types":["condition"],"aliases":["DSWPD"],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_4c462d96e6d960e370e4c4f49ce836e2"},{"public_id":"co_61f8e965026e0633a274e238ca834bbf","status":"active","name":"functional disability","description":"A measure of disability related to sleep impairment, reduced in the melatonin group.","types":["outcome"],"aliases":[],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_61f8e965026e0633a274e238ca834bbf"},{"public_id":"co_a508268843bc8f9338f423ba722c9789","status":"active","name":"dim light melatonin onset","description":"The salivary measure of endogenous melatonin rhythm onset, assessed post-treatment in a subset of patients.","types":["measurement"],"aliases":["DLMO"],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_a508268843bc8f9338f423ba722c9789"},{"public_id":"co_d936f75f654ad55340b0c256595405c2","status":"active","name":"insomnia severity","description":"A measure of the severity of insomnia symptoms, reduced in the melatonin group.","types":["outcome"],"aliases":[],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_d936f75f654ad55340b0c256595405c2"},{"public_id":"co_e0693229cb9b686c92e3f6e525779a05","status":"active","name":"adverse events","description":"Reported side effects including light-headedness, daytime sleepiness, and decreased libido, with similar rates between groups.","types":["observation"],"aliases":[],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_e0693229cb9b686c92e3f6e525779a05"},{"public_id":"co_f6e245900e40a25f4f7b10e3d5de2c19","status":"active","name":"clinician-rated improvement","description":"A clinician-rated assessment of change in illness severity, showing a higher proportion of improvement in the melatonin group.","types":["outcome"],"aliases":[],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_f6e245900e40a25f4f7b10e3d5de2c19"},{"public_id":"co_fc144ee2c1db451da2b3396cf6395629","status":"active","name":"sleep onset time","description":"The primary outcome measured by actigraphy, indicating the time of sleep initiation.","types":["outcome"],"aliases":[],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_fc144ee2c1db451da2b3396cf6395629"}],"external_ids":{"DOI":"10.1371/journal.pmed.1002587","ArXiv":null,"PubMed":29912983,"PubMedCentral":"6005466","MAG":2808725197,"DBLP":null,"ACL":null},"open_access":{"is_open_access":true,"pdf_url":"https://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1002587&type=printable","landing_url":"https://www.semanticscholar.org/paper/cdb706d22841d6ad289f956884c48de8dbc6b58f","source":"semantic_scholar","pdf_url_source":"semantic_scholar_open_access_pdf","license":"CCBY","status":"GOLD","reason":null},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":633847,"paper_uid":"6551b4ce-cc99-413e-9bd5-9e60fb99bd3d","canonical_identity":{"paper_id":633847,"paper_uid":"6551b4ce-cc99-413e-9bd5-9e60fb99bd3d","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/49299569"}